Science

PLOS  Current Outbreaks  by Nadia Wauquier and others                                             April 20, 2015

The initial steps of emergence and spread of a virus are critical in the development of a potential outbreak and need to be thoroughly dissected and understood in order to improve on preventative strategies. In the current West African outbreak of EVD, a unique index case has been identified, pinpointing the geographical origin of the epidemic in Guinea.

Herein, we provide an accounting of events that serve as the footprint of EVD emergence in Sierra Leone and a road map for risk mitigation fueled by lessons learned....

...Continuous active surveillance is needed and must be organized by specialized centers joined in local, regional, and international networks. Surveillance centers must be connected to public health systems and also to research teams for increased understanding and awareness to permit identification and implementation of rapid intervention strategies....

Read complete study  and see maps.

NEW YORK TIMES by Pam Belluck and William J. Broad     April 20, 2015

A growing body of scientific clues — some ambiguous, others substantive — suggests that the Ebola virus may have lurked in the West African rain forest for years, perhaps decades, before igniting the deadly epidemic that swept the region in the past year, taking more than 10,000 lives.

Around 2004 at a government hospital in Kenema, Sierra Leone, a team of American scientists and West African medical personnel found what appeared to be Ebola antibodies in nearly 9 percent of blood samples. Credit Carl De Souza/Agence France-Presse — Getty Images

ICT  INFECTION CONTROL TODAY                                                                  April 14, 2015
(Scroll down for full study)
Research from the University of Manchester using cutting-edge computer analysis reveals that despite mutating, Ebola hasn’t evolved to become deadlier since the first outbreak 40 years ago. The surprising results demonstrate that while a high number of genetic changes have been recorded in the virus, it hasn’t changed at a functional level to become more or less virulent.

The findings, published in the journal Virology, demonstrate that the much higher death toll during the current outbreak, with the figure at nearly 10,500, isn’t due to mutations/evolution making the virus more deadly or more virulent.

As professor Simon Lovell from the Faculty of Life Sciences explains.... What we found was that whilst Ebola is mutating, it isn’t evolving to the point of adapting to become more or less virulent. The function of the virus has remained the same over the past four decades which really surprised us. Unfortunately this does mean the Ebola virus that has now emerged on several occasions since the 1970s will very probably do so again.”

REUTERS by Sharon Bagley                                                                      April 1, 2015

Early-stage trials of an experimental Ebola vaccine, two in the United States and four in Africa and Europe, have found that it appears to be safe and triggered robust production of Ebola-fighting antibodies, scientists reported on Wednesday.

Since trials cannot ethically expose volunteers to Ebola, the production of antibodies is a proxy for whether vaccines could prevent or even treat the disease.

The trials all tested a vaccine called VSV-ZEBOV, which was developed at the Public Health Agency of Canada and licensed to NewLink Genetics Corp and then to Merck & Co Inc. It consists of a cattle virus called rVSV that has been engineered to carry Ebola genes, which produce proteins meant to trigger production of anti-Ebola antibodies.

According to separate teams of scientists, that is what happened, two papers in the New England Journal of Medicine reported.

Read complete story.
http://www.reuters.com/article/2015/04/01/us-health-ebola-vaccine-idUSKBN0MS5DN20150401

Read NEW ENGLAND JOURNAL OF MEDICINE  papers